Details for Patent: 7,820,671

« Back to Dashboard

Which drugs does patent 7,820,671 protect, and when does it expire?

Patent 7,820,671 protects INCIVEK and is included in one NDA.

This patent has ninety-eight patent family members in thirty-four countries.

Summary for Patent: 7,820,671

Title:	Peptidomimetic protease inhibitors
Abstract:	The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
Inventor(s):	Babine; Robert Edward (Carlsbad, CA), Chen; Shu Hui (Thousand Oaks, CA), Collado; Ivan (Madrid, ES), Garcia-Paredes; Cristina (Madrid, ES), Glass; John Irvin (Germantown, MD), Guo; Deqi (Carmel, IN), Jin; Ling (Indianapolis, IN), Lamar; Jason Eric (Indianapolis, IN), Parker, III; Raymond Samuel (Doylestown, PA), Snyder; Nancy June (Lizton, IN), Sun; Xicheng David (Broumfied, CO), Tebbe; Mark Joseph (Zionsville, IN), Victor; Frantz (Indianapolis, IN), Wang; Q. May (Indianapolis, IN), Yip; Yvonne Yee Mai (Indianapolis, IN), Perni; Robert B. (Marlborough, MA), Farmer; Luc (Foxborough, MA)
Assignee:	Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:	10/344,112
Patent Claim Types: see list of patent claims	Compound; Composition;

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011	DISCN	No	No	7,820,671	► Subscribe	Y	Y

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,820,671

PCT Information
PCT Filed	August 31, 2001	PCT Application Number:	PCT/US01/26008
PCT Publication Date:	March 07, 2002	PCT Publication Number:	WO02/18369

Non-Orange Book Patents for Patent: 7,820,671

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,252,923	Peptidomimetic protease inhibitors	► Subscribe
8,529,882	Peptidomimetic protease inhibitors	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,820,671

Country	Document Number	Estimated Expiration
China	101633636	► Subscribe
China	101693672	► Subscribe
China	101696232	► Subscribe
China	102504014	► Subscribe
China	103232381	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 7,820,671

« Back to Dashboard

Summary for Patent: 7,820,671

Glossary

Foreign Priority and PCT Information for Patent: 7,820,671

Non-Orange Book Patents for Patent: 7,820,671

International Patent Family for Patent: 7,820,671

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Get our Free Drug Patent Bulletin